@dansfera: The FDA’s latest move in the biotech world is raising some serious red flags. When regulators demanded a sham surgery as a placebo for a rare disease treatment, many questioned the ethics behind the decision. What was initially labeled an unnecessary and ethically questionable barrier suddenly vanished following a leadership shakeup at the agency. It’s a classic case of bureaucracy versus patient care, and it leaves one wondering just how much control agencies should really have over life-saving innovation. #biotech #fda #medicalethics #Science #regulatoryaffairs